Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation
DO->IT is the overall coordinator of the BD4BO activities within IMI and establishes the mechanisms for a sustainable focus on outcomes based healthcare delivery. DO->IT:
- ensures quality, consistency and sustainability of health outcomes across BD4BO projects
- integrates, synthesises, as well as is responsible for managing knowledge from BD4BO projects for easy access (knowledge exchange platform)
- is a point of collaboration, stakeholder engagement and communication for BD4BO projects
- additionally develops minimum data privacy standards for Informed Consent Forms (ICFs).
Partners:
- London School of Economics and Political Science
- Novartis
- National Institute for Health and Care Excellence
- Dental and Pharmaceutical Benefits Agency
- European Cancer Patient Coalition
- European Multiple Sclerosis Platform
- Semmelweis University
- Imperial College London
- Swedi
- sh Institute for Health Economics
- Centre for Research in Healthcare Management– Università Bocconi
- Norwegian Institute of Public Health
- The Association of the British Pharmaceutical Industry
- Amgen
- Bayer
- Boehringer Ingelheim
- Celgene
- European Federation of Pharmaceutical Industries and Associations
- Farmaindustria
- GlaxoSmithKline
- Health iQ
- InterSystems
- Janssen Pharmaceutica NV
- Eli Lilly and Company
- Merck Group
- MSD Sharp & Dohme
- Novo Nordisk
- Pfizer
- Roche
- Sanofi
- Servier
- UCB
- Association of Research-Based Pharmaceutical Companies
- Norwegian Medicines Agency
- Technology, Methods and Infrastructure for Networked Medical Research
- Inserm Toulouse